MENU
+Compare
SAGE
Stock ticker: NASDAQ
AS OF
Dec 26, 04:59 PM (EDT)
Price
$5.74
Change
+$0.26 (+4.74%)
Capitalization
350.52M

SAGE Sage Therapeutics Forecast, Technical & Fundamental Analysis

a developer of therapeutics and medicines for central nervous system disorders

Industry Biotechnology
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for SAGE with price predictions
Dec 24, 2024

SAGE in upward trend: price may ascend as a result of having broken its lower Bollinger Band on December 18, 2024

SAGE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 42 cases where SAGE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SAGE's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where SAGE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SAGE just turned positive on December 20, 2024. Looking at past instances where SAGE's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SAGE advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 23, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on SAGE as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SAGE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SAGE entered a downward trend on December 02, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.635) is normal, around the industry mean (18.292). P/E Ratio (0.000) is within average values for comparable stocks, (87.498). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.756). SAGE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (3.255) is also within normal values, averaging (260.038).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SAGE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SAGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

SAGE is expected to report earnings to -152 cents per share on February 19

Sage Therapeutics SAGE Stock Earnings Reports
Q4'24
Est.
$-1.53
Q3'24
Beat
by $0.01
Q2'24
Missed
by $0.06
Q1'24
Missed
by $0.15
Q4'23
Beat
by $0.73
The last earnings report on October 29 showed earnings per share of -152 cents, beating the estimate of -153 cents. With 766.25K shares outstanding, the current market capitalization sits at 350.52M.
A.I. Advisor
published General Information

General Information

a developer of therapeutics and medicines for central nervous system disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
215 First Street
Phone
+1 617 299-8380
Employees
487
Web
https://www.sagerx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSCZX51.450.55
+1.08%
Columbia Small Cap Value I Inst
FAPKX13.270.14
+1.07%
Fidelity Advisor Healthy Future C
NSBFX63.380.60
+0.96%
Nuveen Dividend Growth R6
RPPRX30.980.26
+0.85%
Victory RS Partners R6
WELIX9.360.01
+0.11%
William Blair Emerging Mkts Ldrs R6

SAGE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SAGE has been loosely correlated with CRSP. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SAGE jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAGE
1D Price
Change %
SAGE100%
+0.74%
CRSP - SAGE
43%
Loosely correlated
+1.14%
AXON - SAGE
42%
Loosely correlated
+1.14%
ALLO - SAGE
40%
Loosely correlated
+7.18%
HRMY - SAGE
39%
Loosely correlated
-2.55%
MGTX - SAGE
38%
Loosely correlated
+1.31%
More